Amivantamab (JNJ-61186372) 是一种人源可识别表皮生长因子受体 （EGFR） 和 MET 原癌基因 （MET）的抗体，具有抗癌抗肿瘤活性，可防止配体与 EGFR 和 MET 结合以及抑制下游信号转导的受体二聚化。Amivantamab 可诱导巨噬细胞的 Fc 依赖性胞吞作用和自然杀伤细胞的抗体依赖性细胞毒性，可用于研究转移性非小细胞肺癌。

NSC-689857 is an inhibitor that acts in the Skp2-Cks1 protein-protein interaction and p27Kip1 ubiquitination in vitro.

PACAP-38 (31-38), human, mouse, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production.

(3S, 4S)-PF-06459988 is the less active S enantiomer of PF-06459988, which is a potent irreversible inhibitor of T790M mutant epidermal growth factor receptor (EGFR). PF-06459988 exhibits excellent selectivity against EGFR wild-type due to its minimally reactive electrophile, which reduces the likelihood of off-target labeling.

Rociletinib hydrobromide is an orally delivered inhibitor of the mutant form of EGFR kinase (Kis: 21.5 nM and 303.3 nM for EGFR L858R/T790M and EGFR WT).

EGFR/HER2-IN-9 是一种 EGFR 和 HER2抑制剂，对 EGFR、EGFR T790M 和 HER2 的 IC50分别为 3.2、8.3 和 14 nM。